Pharmaron Beijing Co

Pharmaron Beijing Co EBIT Margin

The EBIT Margin (Operating Margin) of Pharmaron Beijing Co (300759.SZ) as of Nov 11, 2026 is 15.78 %. In the previous year, EBIT Margin (Operating Margin) was 17.14 % — a change of -7.93% (lower).

EBIT Margin

15.78 %

YoY

-7.93%

Last updated:

EBIT Margin (Operating Margin) of Pharmaron Beijing Co is 2025 15.78 % . EBIT Margin (Operating Margin) of Pharmaron Beijing Co was 2024 17.14 % . It decreases by -7.93% lower compared to the previous year.

For Pharmaron Beijing Co, the operating (EBIT) margin of 15.8% is down versus 25.7% a few years ago.

The Pharmaron Beijing Co EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
13.50 CNY
Jan 1, 2019
17.70 CNY
Jan 1, 2020
25.79 CNY
Jan 1, 2021
25.72 CNY
Jan 1, 2022
16.46 CNY
Jan 1, 2023
16.02 CNY
Jan 1, 2024
17.14 CNY
Jan 1, 2025
15.78 CNY
The Pharmaron Beijing Co EBIT Margin history
YEAREBIT MarginYoY
15.78 %-7.93%
17.14 %+7.04%
16.02 %-2.70%
16.46 %-35.99%
25.72 %-0.27%
25.79 %+45.66%
17.70 %+31.14%
13.50 %-4.41%
14.12 %+22.76%
11.50 %+77.98%
6.46 %+107.56%
3.11 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Pharmaron Beijing Co Stock analysis

What does Pharmaron Beijing Co do? Pharmaron Beijing Co Ltd generates revenue through four business segments. The Laboratory Services segment offers laboratory chemistry, drug metabolism, pharmacokinetics, absorption, distribution, metabolism, and excretion testing, biology, safety assessment, and discovery of biological agents. The CMC Service segment provides process development, preform production, and analysis for drug manufacturing. The Clinical Development Service segment delivers clinical research, on-site management organization, regulatory biological analysis, and radioactive labeling scientific services. The Biologics and CGT Services segment focuses on macromolecular drug discovery, development, and production, alongside cell gene therapy method development. These services are primarily purchased by pharmaceutical companies and biotechnology firms engaged in drug discovery and development processes. Pharmaron Beijing Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pharmaron Beijing Co stock

EBIT Margin (Operating Margin) of Pharmaron Beijing Co is 15.78 % in 2025.

EBIT Margin (Operating Margin) of Pharmaron Beijing Co changed from 17.14 % to 15.78 %, representing a -7.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Pharmaron Beijing Co since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Pharmaron Beijing Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Pharmaron Beijing Co

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Pharmaron Beijing Co